Omalizumab (Xolair) subcutaneous injection — Coverage Criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, initial and continuation coverage criteria, site-of-care rules, dosing limits, and documentation requirements for omalizumab (Xolair) administered by a healthcare professional for Blue Cross NC members.
For CRSwNP indication: added requirement of at least two inadequately controlled symptoms for ≥12 consecutive weeks and diagnostic confirmation by anterior rhinoscopy, nasal endoscopy, or sinus CT imaging.
Removed required trial and failure of Xhance or oral systemic corticosteroids for CRSwNP and replaced with requirement for intranasal corticosteroid trial of at least 4 weeks within prior 12 weeks.
Adjusted verbiage to require that patients currently treated with an intranasal corticosteroid will continue that therapy when starting omalizumab for CRSwNP.
For asthma initial criteria: reformatted exacerbation history language for clarity without changing intent; added explicit requirement to continue asthma control therapy when using omalizumab as add-on maintenance.
Updated list of biologic immunomodulators that must not be used concomitantly to include newer agents (e.g., remibrutinib [Rhapsido]).
Added new indication for Xolair for IgE-mediated food allergy in patients 1 year and older.
For urticaria: required symptoms for ≥6 weeks and added requirement for dose reduction/discontinuation of medications that cause/worsen urticaria or documentation that it's not appropriate.
Coverage and Medical Necessity Criteria
Initial Therapy - Asthma
Covered when ALL of the following are met:
Initial Therapy - Chronic Spontaneous Urticaria (CSU)
Covered when ALL of the following are met:
Initial Therapy - Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Covered when ALL of the following are met:
Initial Therapy - IgE-mediated Food Allergy
Covered when ALL of the following are met:
Continuation Therapy
Covered when ALL of the following are met:
CRSwNP Initial Therapy
CRSwNP initial therapy covered when ALL of the following are met:
Removed prior requirement for trial/failure of Xhance or oral systemic corticosteroids; examples of nasal polyp surgery listed in policy.
CRSwNP Continuation Therapy
CRSwNP continuation covered when ALL of the following are met:
Continuation criteria adjusted to require documented positive clinical response and continuation of intranasal corticosteroid therapy.
Asthma
Covered when ALL of the following are met:
Chronic Spontaneous Urticaria
Chronic spontaneous urticaria (CSU) initial and continuation:
IgE-mediated Food Allergy
Covered when ALL of the following are met:
Omalizumab (Xolair) is not indicated for emergency treatment. Specifically, this policy excludes use for the emergency treatment of allergic reactions, including anaphylaxis, and for relief of acute bronchospasm or status asthmaticus. The agent is also not covered for other forms of urticaria outside of chronic spontaneous urticaria (CSU). These limitations align with the FDA labeled uses and the policy's scope of approved indications.
Concomitant administration of omalizumab with other biologic immunomodulators for the same indication is prohibited. The policy lists specific examples of disallowed combinations and has been updated to include newer agents such as remibrutinib (Rhapsido). Providers must confirm the member is not receiving another biologic immunomodulator (e.g., benralizumab, depemokimab, dupilumab, mepolizumab, reslizumab, remibrutinib, tezepelumab-ekko) when requesting coverage.
Site-of-care rules apply to requests for facility-based administration. An inpatient admission solely for the purpose of administering an injection or infusion is not allowed; the inpatient stay must be for reasons other than administration of omalizumab. For outpatient hospital administration, the policy requires the medical necessity criteria plus at least one site-of-care bypass condition (for example, history of a severe adverse event, unstable comorbid condition, recent initiation of therapy, documented inability to adhere, or other specified clinical circumstances). If the site-of-care criteria are not met, administration should occur in a home infusion or physician office setting.
Requests that exceed the policy's dosing limits or that lack required prior or concurrent therapy documentation will be considered not medically necessary. For chronic spontaneous urticaria, for example, doses that exceed 300 mg every 4 weeks are outside covered limits. Similarly, failure to document required prior trials, ongoing concomitant therapies, or other mandated clinical information may lead to denial of coverage.
Prior Authorization, Documentation, and Step Therapy Actions
Prior Authorization Required
Prior authorization is required for the requested agent. Requests must meet the policy criteria and specify HCPCS/other applicable drug codes. Failure to obtain prior authorization may result in claim denial or delay.
- Prior authorization required — requests must include HCPCS J2357 (if applicable) and relevant drug code(s).
- Requests must meet all indication-specific criteria in the policy.
Prior Authorization — Indication-Specific Documentation
Prior authorization requests must include indication-specific documentation to support medical necessity. Missing or incomplete documentation may result in denial.
- Diagnostic confirmation (see CRSwNP requirements below).
- Documentation of prior and concurrent therapy trials and adherence.
- Symptom duration and severity records where applicable.
Step Therapy and Prior Treatment Trials
Step therapy requirements apply for certain indications. Document all prior treatment trials, the duration of each trial, and reason for failure (inadequate response, intolerance, or contraindication).
- For chronic spontaneous urticaria (CSU): trial of a second-generation H1 antihistamine (dose-titrated up to at least 2x FDA labeled maximum) unless intolerance, hypersensitivity, or contraindication is documented.
- For other indications, document trials of conventional therapies as specified in the criteria (e.g., inhaled corticosteroids and an additional controller for asthma).
Step Therapy Requirements
Specific step therapy expectations and acceptable documentation are listed below. If the required prior therapies were not tried or documentation is insufficient, the request may be denied.
- CSU: Record of trial and inadequate response to dose-titrated second-generation H1 antihistamine (or documented intolerance/contraindication).
- CRSwNP: Trial of an intranasal corticosteroid for at least 4 consecutive weeks within 12 weeks prior to therapy initiation, or documented intolerance/contraindication to all intranasal corticosteroids.
- Asthma: Documented use and adherence to a maximally tolerated inhaled corticosteroid regimen for the past 3 months and an additional controller (LABA, LTRA, LAMA, theophylline, or zileuton) as specified.
Required Medical Record Documentation
Medical record documentation required to support initial and continuation approval includes objective testing, prior therapy records, and evidence of adherence or clinical justification for exceptions.
- Pre-treatment IgE level where applicable (e.g., asthma criteria: 30–1300 IU/mL for ages 6–11; 30–700 IU/mL for ages ≥12).
- Positive skin test or in vitro reactivity to a perennial aeroallergen for IgE-mediated indications.
- Documentation of trials, durations, and outcomes for prior therapies (including dates and doses).
- Evidence of adherence to required background therapies (e.g., inhaled corticosteroid regimen for asthma; intranasal corticosteroid for CRSwNP).
CRSwNP Diagnostic Documentation — Denial Risk if Incomplete
For chronic rhinosinusitis with nasal polyposis (CRSwNP), requests lacking the required diagnostic documentation will be at high risk for denial.
- Documentation that the patient had at least two inadequately controlled CRS-consistent symptoms (nasal obstruction/congestion, nasal discharge, facial pain/pressure, or reduction/loss of smell) for at least 12 consecutive weeks prior to therapy initiation.
- Diagnostic confirmation by anterior rhinoscopy, nasal endoscopy, or CT scan of the sinuses (report or images in the record).
- Documentation of prior nasal polyp surgery or a documented reason why the patient is not a candidate for surgery, when applicable.
Prior/Concurrent Therapy Documentation — Denial Risk if Missing
Requests will be denied if required prior or concurrent therapies are not documented. Ensure records show trials, adherence, or documented contraindications/intolerances.
- CRSwNP: Evidence of trial and inadequate response to an intranasal corticosteroid for at least 4 consecutive weeks within 12 weeks prior to initiation, or documentation of intolerance/contraindication to all intranasal corticosteroids.
- Asthma: Documentation that the patient is currently treated with and adherent to inhaled corticosteroid therapy and an additional controller regimen as specified in the criteria, and that the patient will continue concurrent asthma control therapy.
- CSU and other indications: Documentation of prior recommended therapies, dose titration attempts, and reasons for discontinuation or failure (inadequate response, intolerance, contraindication).
Documentation and Criteria Noncompliance — Risk of Denial
Failure to provide required documentation (e.g., IgE level, skin test results, trial of required therapies, adherence evidence, diagnostic imaging/reports) will place the request at substantial risk for denial.
- Common deficiencies include missing pre-treatment IgE, absent positive skin or in vitro testing, lack of documented trials or outcomes for step therapy, and absent evidence of adherence to background medications.
- When exceptions are claimed (e.g., intolerance or contraindication), include clear medical record evidence supporting the exception.
Billing Codes, Dosing Limits, and Lab Requirements
| J2357 | Omalizumab injection, per 150 mg |
Definitions and Background
This policy defines the scope of coverage and key caveats: omalizumab is approved as an add-on maintenance therapy for specified, FDA‑labeled indications and is not for acute or emergency use. Prior authorization is required and requests must include indication‑specific documentation (diagnostic confirmation, prior/concurrent therapy trials and adherence, pre‑treatment IgE where applicable). Site-of-care criteria govern inpatient and outpatient hospital administration; inpatient admissions solely for administration are not acceptable. The policy also prohibits combination use with other biologic immunomodulators for the same indication and enforces indication‑specific dosing ceilings and required trials of conventional therapies.
Omalizumab (Xolair) is a monoclonal antibody that binds circulating IgE and is used as an add‑on maintenance therapy for several IgE‑mediated conditions. FDA‑approved indications include moderate‑to‑severe persistent asthma in patients aged ≥6 years with positive skin test or in vitro reactivity to a perennial aeroallergen, chronic spontaneous urticaria in patients aged ≥12 years who remain symptomatic despite H1 antihistamines, chronic rhinosinusitis with nasal polyps in adults with inadequate response to nasal corticosteroids, and IgE‑mediated food allergy in patients aged ≥1 year to reduce allergic reactions when used alongside avoidance. The drug is not intended for emergency treatment of allergic reactions, including anaphylaxis, nor for treatment of other forms of urticaria or relief of acute bronchospasm/status asthmaticus.
Policy Revision History
For CRSwNP: added requirement of ≥2 inadequately controlled symptoms for ≥12 consecutive weeks and diagnostic confirmation by anterior rhinoscopy, nasal endoscopy, or sinus CT; replaced prior Xhance/OCS trial requirement with an intranasal corticosteroid trial of ≥4 consecutive weeks within prior 12 weeks; added requirement for documented positive clinical response for CRSwNP continuation and that patients continue intranasal corticosteroid therapy.
Updated CRSwNP continuation criteria to require adherence to an over-the-counter intranasal steroid since starting Xolair; updated no-concomitant-use statements to include Rhapsido and added additional Site of Care bypass language.
For asthma: reformatted and separated asthma criteria with added requirement for documentation of current, adherent treatment with maximally tolerated conventional therapies for past 3 months and requirement that patient continue asthma control therapy when using omalizumab; for CSU: added symptom duration (≥6 weeks), required dose reduction/discontinuation of medications that worsen urticaria or documentation why not appropriate, and reformatted H1 antihistamine trial.
Added new indication for IgE-mediated food allergy for patients aged ≥1 year with corresponding dosing table updates and maximum units.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.